Additional file 1 of 68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer

Additional file 1: of Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience

Felipe Couñago (3528257)
Manuel Recio (3528239)
Antonio Maldonado (317525)
Elia del Cerro (3528242)
Ana Díaz-Gavela (3528251)
Israel Thuissard (3528260)
David Sanz-Rosa (3528245)
Francisco Marcos (3528254)
Karmele Olaciregui (3528248)
María Mateo (3528236)
Laura Cerezo (3528233)

December 2016

Comparison of the clinical variables of patients with positive and negative local recurrence. (DOC 6...

Additional file 2: of Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference

Constantinos Zamboglou (364809)
Benedikt Thomann (5096807)
Khodor Koubar (5162633)
Peter Bronsert (3410321)
Tobias Krauss (5162627)
Hans Rischke (5096813)
Ilias Sachpazidis (5162624)
Vanessa Drendel (700868)
Nasr Salman (5162636)
Kathrin Reichel (5162630)
Cordula Jilg (3770989)
Martin Werner (281835)
Philipp Meyer (2042710)
Michael Bock (541214)
Dimos Baltas (5096810)
Anca Grosu (4637779)

May 2018

Tables S2aâ+âb. 1. FLAME protocol / 2. Pinkawa protocol. Dose characteristics after IMRT plannin...

Additional file 1: of Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control

Per Munck af Rosenschold (3996257)
Michael Zelefsky (4253701)
Aditya Apte (5096630)
Andrew Jackson (376958)
Jung Oh (3454469)
Elliot Shulman (5096636)
Neil Desai (5096627)
Margie Hunt (4253710)
Pirus Ghadjar (3538115)
Ellen Yorke (839323)
Joseph Deasy (5096633)

April 2018

Table S1. The patient characteristics, for patients experiencing PSA relapse and control, respective...

Additional file 1 of PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

Hui Wang (11310555)
Thomas Amiel (11310558)
Christoph Würnschimmel (11310561)
Thomas Langbein (11310564)
Katja Steiger (831771)
Isabel Rauscher (8396568)
Thomas Horn (10130)
Tobias Maurer (4896895)
Wolfgang Weber (1390167)
Hans-Juergen Wester (43799)
Karina Knorr (11310567)
Matthias Eiber (4896889)

August 2021

Additional file 1. Supplementary files. Supplementary table 1. Distribution of pT and miT. Supplemen...

Additional file 1 of Development and validation of 68Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer

Shiming Zang (13886633)
Shuyue Ai (13886636)
Rui Yang (293531)
Pengjun Zhang (157743)
Wenyu Wu (129369)
Zhenyu Zhao (737165)
Yudan Ni (9510871)
Qing Zhang (1802)
Hongbin Sun (113935)
Hongqian Guo (717916)
Ruipeng Jia (694922)
Feng Wang (13886639)

September 2022

Additional file 1: Table S1. Configuration settings of radiomics in the study. Table S2. The nine fe...

Additional file 1 of Evaluation of [68 Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria

Daniel Koehler (13931099)
Markus Sauer (16847)
Amir Karimzadeh (13931102)
Ivayla Apostolova (832129)
Susanne Klutmann (13265400)
Gerhard Adam (645067)
Sophie Knipper (13931105)
Tobias Maurer (4896895)
Christoph Berliner (13931108)

October 2022

Additional file1. Table S1. Gemini GXL 10: Cases with changes of lesion interpretation in biphasic i...

Additional file 11: of Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Jing Chen (4762)
Shunwang Cao (5338076)
Bo Situ (4682563)
Juan Zhong (486982)
Yanwei Hu (766578)
Shufen Li (746508)
Jinlan Huang (4615594)
Jiasen Xu (729951)
Shiyang Wu (729947)
Jinduan Lin (5338073)
Qianwen Zhao (5467433)
Zhen Cai (576458)
Lei Zheng (106363)
Qian Wang (32718)

June 2018

Table S7. Metabolic and EMT subtypes of CTCs in non-metastatic and metastatic PCa patients (Cohort 2...

Additional file 3: of Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

Katharina Lückerath (501131)
Liu Wei (523140)
Wolfgang Fendler (5907353)
Susan Evans-Axelsson (2632642)
Andreea Stuparu (5907359)
Roger Slavik (1594090)
Christine Mona (5907362)
Jeremie Calais (5907365)
Matthew Rettig (146731)
Robert Reiter (5907368)
Ken Herrmann (711717)
Caius Radu (3400175)
Johannes Czernin (1344825)
Matthias Eiber (4896889)

December 2018

Table S1. Fold-change in tumor volume, 68Ga-PSMA11 uptake, and PSMA levels as assessed by flow cytom...

Ga-68 PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer

Iravani, A
Hofman, MS
Mulcahy, T
Williams, S
Murphy, D
Parameswaran, BK
Hicks, RJ

December 2017

BACKGROUND: 68Ga-labelled prostate specific membrane antigen (PSMA) ligand PET/CT is a promising mod...

Additional file 4: of Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference

Constantinos Zamboglou (364809)
Benedikt Thomann (5096807)
Khodor Koubar (5162633)
Peter Bronsert (3410321)
Tobias Krauss (5162627)
Hans Rischke (5096813)
Ilias Sachpazidis (5162624)
Vanessa Drendel (700868)
Nasr Salman (5162636)
Kathrin Reichel (5162630)
Cordula Jilg (3770989)
Martin Werner (281835)
Philipp Meyer (2042710)
Michael Bock (541214)
Dimos Baltas (5096810)
Anca Grosu (4637779)

May 2018

Figure S1. Dose volume histograms (DVHs) for GTV-histo, averaged for all plans and all patients. (PD...

68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer

Amir Iravani
Michael S. Hofman
Tony Mulcahy
Scott Williams
Declan Murphy
Bimal K. Parameswaran
Rodney J. Hicks

December 2017

Abstract Background 68Ga-labelled prostate specific membrane antigen (PSMA) ligand PET/CT is a promi...

Additional file 1: of Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy

B. Meller (3767254)
F. Bremmer (3767257)
C. Sahlmann (3767242)
S. Hijazi (3767245)
C. Bouter (3767263)
L. Trojan (3767251)
J. Meller (3767248)
P. Thelen (3767260)

November 2015

68 Ga-HBED-CC Radio-HPLC. Quality control of a regular Ga-HBED-CC synthesis. Radiochemical purity wa...

Additional file 5: of Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

Katharina Lückerath (501131)
Liu Wei (523140)
Wolfgang Fendler (5907353)
Susan Evans-Axelsson (2632642)
Andreea Stuparu (5907359)
Roger Slavik (1594090)
Christine Mona (5907362)
Jeremie Calais (5907365)
Matthew Rettig (146731)
Robert Reiter (5907368)
Ken Herrmann (711717)
Caius Radu (3400175)
Johannes Czernin (1344825)
Matthias Eiber (4896889)

December 2018

Table S3. Fold-change in C4-2 tumor volume following PSMA-RLT. Mean ± SD are given. (DOCX 14 kb

Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.

Fanti S
MINOZZI, SIMONA
Morigi JJ
Giesel F
Ceci F
Uprimny C
Hofman MS
Eiber M
Schwarzenbock S
Castellucci P
Bellisario C
Chauvie S
Bergesio F
Emmett L
Haberkorn U
Virgolini I
Schwaiger M
Hicks RJ
Krause BJ
Chiti A.

January 2017

METHODS: After primary treatment, biochemical relapse (BCR) occurs in a substantial number of pa...

Additional file 2 of FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Matthew Scarpelli (6279719)
Christopher Zahm (6279722)
Scott Perlman (6279725)
Douglas McNeel (6279728)
Robert Jeraj (6279731)
Glenn Liu (6279734)

January 2019

Table S1. Baseline FLT SUVs, tumor size measurements, and PSA levels were included in Cox proportion...

Additional file 1: of Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience

Felipe Couñago (3528257)
Manuel Recio (3528239)
Antonio Maldonado (317525)
Elia del Cerro (3528242)
Ana Díaz-Gavela (3528251)
Israel Thuissard (3528260)
David Sanz-Rosa (3528245)
Francisco Marcos (3528254)
Karmele Olaciregui (3528248)
María Mateo (3528236)
Laura Cerezo (3528233)

December 2016

Comparison of the clinical variables of patients with positive and negative local recurrence. (DOC 6...

Additional file 2: of Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference

Constantinos Zamboglou (364809)
Benedikt Thomann (5096807)
Khodor Koubar (5162633)
Peter Bronsert (3410321)
Tobias Krauss (5162627)
Hans Rischke (5096813)
Ilias Sachpazidis (5162624)
Vanessa Drendel (700868)
Nasr Salman (5162636)
Kathrin Reichel (5162630)
Cordula Jilg (3770989)
Martin Werner (281835)
Philipp Meyer (2042710)
Michael Bock (541214)
Dimos Baltas (5096810)
Anca Grosu (4637779)

May 2018

Tables S2aâ+âb. 1. FLAME protocol / 2. Pinkawa protocol. Dose characteristics after IMRT plannin...

Additional file 1: of Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control

Per Munck af Rosenschold (3996257)
Michael Zelefsky (4253701)
Aditya Apte (5096630)
Andrew Jackson (376958)
Jung Oh (3454469)
Elliot Shulman (5096636)
Neil Desai (5096627)
Margie Hunt (4253710)
Pirus Ghadjar (3538115)
Ellen Yorke (839323)
Joseph Deasy (5096633)

April 2018

Table S1. The patient characteristics, for patients experiencing PSA relapse and control, respective...

Additional file 1 of PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

Hui Wang (11310555)
Thomas Amiel (11310558)
Christoph Würnschimmel (11310561)
Thomas Langbein (11310564)
Katja Steiger (831771)
Isabel Rauscher (8396568)
Thomas Horn (10130)
Tobias Maurer (4896895)
Wolfgang Weber (1390167)
Hans-Juergen Wester (43799)
Karina Knorr (11310567)
Matthias Eiber (4896889)

August 2021

Additional file 1. Supplementary files. Supplementary table 1. Distribution of pT and miT. Supplemen...

Additional file 1 of Development and validation of 68Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer

Shiming Zang (13886633)
Shuyue Ai (13886636)
Rui Yang (293531)
Pengjun Zhang (157743)
Wenyu Wu (129369)
Zhenyu Zhao (737165)
Yudan Ni (9510871)
Qing Zhang (1802)
Hongbin Sun (113935)
Hongqian Guo (717916)
Ruipeng Jia (694922)
Feng Wang (13886639)

September 2022

Additional file 1: Table S1. Configuration settings of radiomics in the study. Table S2. The nine fe...

Additional file 1 of Evaluation of [68 Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria

Daniel Koehler (13931099)
Markus Sauer (16847)
Amir Karimzadeh (13931102)
Ivayla Apostolova (832129)
Susanne Klutmann (13265400)
Gerhard Adam (645067)
Sophie Knipper (13931105)
Tobias Maurer (4896895)
Christoph Berliner (13931108)

October 2022

Additional file1. Table S1. Gemini GXL 10: Cases with changes of lesion interpretation in biphasic i...

Additional file 11: of Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Jing Chen (4762)
Shunwang Cao (5338076)
Bo Situ (4682563)
Juan Zhong (486982)
Yanwei Hu (766578)
Shufen Li (746508)
Jinlan Huang (4615594)
Jiasen Xu (729951)
Shiyang Wu (729947)
Jinduan Lin (5338073)
Qianwen Zhao (5467433)
Zhen Cai (576458)
Lei Zheng (106363)
Qian Wang (32718)

June 2018

Table S7. Metabolic and EMT subtypes of CTCs in non-metastatic and metastatic PCa patients (Cohort 2...

Additional file 3: of Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

Katharina Lückerath (501131)
Liu Wei (523140)
Wolfgang Fendler (5907353)
Susan Evans-Axelsson (2632642)
Andreea Stuparu (5907359)
Roger Slavik (1594090)
Christine Mona (5907362)
Jeremie Calais (5907365)
Matthew Rettig (146731)
Robert Reiter (5907368)
Ken Herrmann (711717)
Caius Radu (3400175)
Johannes Czernin (1344825)
Matthias Eiber (4896889)

December 2018

Table S1. Fold-change in tumor volume, 68Ga-PSMA11 uptake, and PSMA levels as assessed by flow cytom...

Ga-68 PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer

Iravani, A
Hofman, MS
Mulcahy, T
Williams, S
Murphy, D
Parameswaran, BK
Hicks, RJ

December 2017

BACKGROUND: 68Ga-labelled prostate specific membrane antigen (PSMA) ligand PET/CT is a promising mod...

Additional file 4: of Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference

Constantinos Zamboglou (364809)
Benedikt Thomann (5096807)
Khodor Koubar (5162633)
Peter Bronsert (3410321)
Tobias Krauss (5162627)
Hans Rischke (5096813)
Ilias Sachpazidis (5162624)
Vanessa Drendel (700868)
Nasr Salman (5162636)
Kathrin Reichel (5162630)
Cordula Jilg (3770989)
Martin Werner (281835)
Philipp Meyer (2042710)
Michael Bock (541214)
Dimos Baltas (5096810)
Anca Grosu (4637779)

May 2018

Figure S1. Dose volume histograms (DVHs) for GTV-histo, averaged for all plans and all patients. (PD...

68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer

Amir Iravani
Michael S. Hofman
Tony Mulcahy
Scott Williams
Declan Murphy
Bimal K. Parameswaran
Rodney J. Hicks

December 2017

Abstract Background 68Ga-labelled prostate specific membrane antigen (PSMA) ligand PET/CT is a promi...

Additional file 1: of Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy

B. Meller (3767254)
F. Bremmer (3767257)
C. Sahlmann (3767242)
S. Hijazi (3767245)
C. Bouter (3767263)
L. Trojan (3767251)
J. Meller (3767248)
P. Thelen (3767260)

November 2015

68 Ga-HBED-CC Radio-HPLC. Quality control of a regular Ga-HBED-CC synthesis. Radiochemical purity wa...

Additional file 5: of Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

Katharina Lückerath (501131)
Liu Wei (523140)
Wolfgang Fendler (5907353)
Susan Evans-Axelsson (2632642)
Andreea Stuparu (5907359)
Roger Slavik (1594090)
Christine Mona (5907362)
Jeremie Calais (5907365)
Matthew Rettig (146731)
Robert Reiter (5907368)
Ken Herrmann (711717)
Caius Radu (3400175)
Johannes Czernin (1344825)
Matthias Eiber (4896889)

December 2018

Table S3. Fold-change in C4-2 tumor volume following PSMA-RLT. Mean ± SD are given. (DOCX 14 kb

Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.

Fanti S
MINOZZI, SIMONA
Morigi JJ
Giesel F
Ceci F
Uprimny C
Hofman MS
Eiber M
Schwarzenbock S
Castellucci P
Bellisario C
Chauvie S
Bergesio F
Emmett L
Haberkorn U
Virgolini I
Schwaiger M
Hicks RJ
Krause BJ
Chiti A.

January 2017

METHODS: After primary treatment, biochemical relapse (BCR) occurs in a substantial number of pa...

Additional file 2 of FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Matthew Scarpelli (6279719)
Christopher Zahm (6279722)
Scott Perlman (6279725)
Douglas McNeel (6279728)
Robert Jeraj (6279731)
Glenn Liu (6279734)

January 2019

Table S1. Baseline FLT SUVs, tumor size measurements, and PSA levels were included in Cox proportion...

Additional file 1: of Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience

Felipe Couñago (3528257)
Manuel Recio (3528239)
Antonio Maldonado (317525)
Elia del Cerro (3528242)
Ana Díaz-Gavela (3528251)
Israel Thuissard (3528260)
David Sanz-Rosa (3528245)
Francisco Marcos (3528254)
Karmele Olaciregui (3528248)
María Mateo (3528236)
Laura Cerezo (3528233)

December 2016

Comparison of the clinical variables of patients with positive and negative local recurrence. (DOC 6...

Additional file 2: of Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference

Constantinos Zamboglou (364809)
Benedikt Thomann (5096807)
Khodor Koubar (5162633)
Peter Bronsert (3410321)
Tobias Krauss (5162627)
Hans Rischke (5096813)
Ilias Sachpazidis (5162624)
Vanessa Drendel (700868)
Nasr Salman (5162636)
Kathrin Reichel (5162630)
Cordula Jilg (3770989)
Martin Werner (281835)
Philipp Meyer (2042710)
Michael Bock (541214)
Dimos Baltas (5096810)
Anca Grosu (4637779)

May 2018

Tables S2aâ+âb. 1. FLAME protocol / 2. Pinkawa protocol. Dose characteristics after IMRT plannin...

Additional file 1: of Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control

Per Munck af Rosenschold (3996257)
Michael Zelefsky (4253701)
Aditya Apte (5096630)
Andrew Jackson (376958)
Jung Oh (3454469)
Elliot Shulman (5096636)
Neil Desai (5096627)
Margie Hunt (4253710)
Pirus Ghadjar (3538115)
Ellen Yorke (839323)
Joseph Deasy (5096633)

April 2018

Table S1. The patient characteristics, for patients experiencing PSA relapse and control, respective...

Additional file 1 of 68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer

Abstract

Extracted data

Additional file 1 of 68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer

Abstract

Extracted data

Related items

Related items